uniQure N.V. (NASDAQ:QURE) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of uniQure N.V. (NASDAQ:QURE) have received an average recommendation of “Moderate Buy” from the seventeen brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $42.75.

Several equities analysts have issued reports on the stock. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $15.00 to $60.00 in a report on Monday, March 9th. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $11.00 to $35.00 in a research note on Monday, March 9th. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of uniQure in a research report on Tuesday, March 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Finally, Leerink Partners reiterated an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a report on Monday, March 2nd.

Insiders Place Their Bets

In related news, insider Jeannette Potts sold 3,412 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider directly owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares in the company, valued at $557,575.92. The trade was a 23.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 81,399 shares of company stock valued at $1,527,645. 4.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently modified their holdings of the business. Swiss National Bank purchased a new stake in uniQure during the 2nd quarter valued at about $1,080,000. Sanders Morris Harris LLC purchased a new position in uniQure in the 3rd quarter worth approximately $5,081,000. Vanguard Group Inc. lifted its stake in uniQure by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after purchasing an additional 152,417 shares in the last quarter. Aberdeen Group plc boosted its holdings in shares of uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares during the last quarter. Finally, Voss Capital LP acquired a new position in shares of uniQure during the 2nd quarter worth approximately $1,742,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: Hagens Berman updates its probe into uniQure following public FDA criticism and allegations that data were distorted — a development that amplifies regulatory and litigation risk. QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears
• Negative Sentiment: Hagens Berman issues a separate shareholder alert alleging public FDA rebukes and “distorted” data, reinforcing the narrative of potential securities claims and reputational damage. QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data
• Negative Sentiment: Robbins LLP reminds investors of a class action covering purchases from Sept. 24–Oct. 31, 2025, signaling additional potential plaintiffs and litigation costs. uniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm for Information About Their Rights
• Negative Sentiment: ClaimsFiler warns investors of the April 13 deadline to apply for lead‑plaintiff status in the securities class action — a near‑term administrative catalyst that may increase filings. uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. – QURE
• Negative Sentiment: Rosen Law Firm issues a deadline reminder for purchasers in the Sept.–Oct. 2025 class period, reinforcing the expectation of continued legal activity. UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action – QURE
• Negative Sentiment: Bragar Eagel & Squire and other firms (Pomerantz, Schall Law Firm, etc.) are soliciting large‑loss investors and offering to pursue lead‑plaintiff status, indicating multiple firms are competing to litigate — a sign of escalating legal attention. UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th
• Negative Sentiment: Pomerantz and The Schall Law Firm similarly remind investors of the class action and filing deadlines, adding to the chorus of litigation notices that can increase legal expenses and distract management. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE
• Negative Sentiment: Local/regional outlets republished firm notices (Rosen, Bragar, Rosen deadline stories), increasing visibility of the litigation and potentially pressuring retail holders to sell. UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure …

uniQure Price Performance

uniQure stock opened at $17.16 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The stock has a market capitalization of $1.07 billion, a PE ratio of -4.97 and a beta of 0.75. The business has a 50 day simple moving average of $19.26 and a 200-day simple moving average of $29.40. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. On average, analysts anticipate that uniQure will post -3.75 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.